Role of pharmacogenomics in host response to treatment

L. Rosenwasser (Denver, United States Of America)

Source: Annual Congress 2004 - PG7 - Application of genomics and proteomics to pulmonary disease
Session: PG7 - Application of genomics and proteomics to pulmonary disease
Session type: Postgraduate Course
Number: 47

PDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Rosenwasser (Denver, United States Of America). Role of pharmacogenomics in host response to treatment. Annual Congress 2004 - PG7 - Application of genomics and proteomics to pulmonary disease

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Role of altered immune response in CF and implication for antiinflammatory therapies
Source: Research Seminar 2012 - Pulmonary inflammation in paediatric respiratory disease
Year: 2012

Dysregulation of host defence peptides by environmental challenge: Can we mitigate the pathophysiology?
Source: International Congress 2019 – Infections, the microbiome and host defence peptides in the development and progression of asthma
Year: 2019

Oral presentation: Targeting of microRNAs can restore innate anti-viral response in asthma
Source: Lung Science Conference 2014 - Lung Inflammation and Immunity
Year: 2014

Role of adaptive immunity in clinical variability of active tuberculosis patients
Source: Virtual Congress 2021 – Novel imaging analysis methodologies in diffuse lung diseases
Year: 2021

Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma
Source: Eur Respir J, 53 (2) 1802444; 10.1183/13993003.02444-2018
Year: 2019

Immunology and defence mechanism of the developing lung
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-50-2, page=60
Year: 2006

Role of immune cells
Source: International Congress 2015 – PG6 Cell-matrix dynamics in lung injury and repair
Year: 2015

Improving the innate immune response in respiratory infections: the use of repurposed drugs
Source: Virtual Congress 2020 – Antibiotic resistance: the way forward
Year: 2020

Immunotherapy improves inflammatory response and lymphocyte apoptosis as a new therapeutic target in sepsis rat
Source: Annual Congress 2009 - Severe sepsis and multiple organ failure
Year: 2009

Targeting the arginase pathway: potential developments as new avenues for treatment
Source: Annual Congress 2004 - Arginase: a novel target and marker for asthma?
Year: 2004

Optimizing the target therapy development
Source: ERS Research Seminar
Year: 2015

Delivery of siRNA to the lungs and airways
Source: Annual Congress 2005 - Selective gene knockout - the use of small interference RNA
Year: 2005

The microbiome, cancer development and response to therapy
Source: International Congress 2018 – Scientific Year in Review
Year: 2018

Precision medicine in tuberculosis treatment – a role for pharmacogenetics?
Source: International Congress 2018 – Challenges in tuberculosis care
Year: 2018

Dynamics of IFN-ß responses during respiratory viral infection: insights for therapeutic strategies
Source: International Congress 2019 – Mechanisms underlying respiratory infection
Year: 2019

Regulation of immune response plasticity – A path to success in pulmonary diseases management
Source: Annual Congress 2012 - Cell biology and inflammatory gene expression in chronic lung disease
Year: 2012

ICS/LABA effects on antiviral innate immune response. An in vitro analysis.
Source: International Congress 2019 – Novel targets and mechanisms in asthma
Year: 2019

Host response (immune response)
Source: Virtual Congress 2020 – Basic science
Year: 2020